Navigation Links
MGC Diagnostics Corporation Reports Fourth Quarter and Fiscal Year 2012 Operating Results
Date:12/19/2012

ef Financial Officer

(602) 889-9700(651) 484-4874

mgcd@lythampartners.com(Financial Tables to Follow)MCG DIAGNOSTICS CORPORATION AND SUBSIDIARIESConsolidated Balance Sheets(In thousands, except share and per share data) October 31, October 31, 20122011AssetsCurrent Assets:Cash and cash equivalents

$
9,665$
8,461Short-term investments

-723Accounts receivable, net of allowance for doubtfulaccounts of $98 and $96, respectively

5,8605,958Inventories, net of obsolescence reserve of $373 and$431, respectively

3,8503,688Prepaid expenses and other current assets

418235Current assets of discontinued operations

-62Total current assets

19,79319,127Property and equipment, net of accumulated depreciation of $3,876 and $3,735, respectively

578440Intangible assets, net

1,4921,174Other non-current assets

85-Non-current assets of discontinued operations

-31Total Assets$
21,948$
20,772Liabilities and Shareholders' EquityCurrent Liabilities:Accounts payable

$
2,094$
2,022Employee compensation

1,7491,481Deferred income

1,9271,771Warranty reserve

91141Other current liabilities and accrued expenses

442221Total current liabilities

6,3035,636Long-term liabilities:Long-term deferred income and other

895817Total Liabilities7,1986,453Commitments and Contingencies--Shareholders' Equity:Common stock, $0.10 par value, authorized 25,000,000 shares,3,986,350 and 3,905,648 shares issued and 3,885,279 and3,778,796 shares outstanding in 2012 and 2011, respectively

388378Undesignated shares, authorized 5,000,000 shares,no shares issued and outstanding

--Additional paid-in capital

21,04620,622Accumulated deficit

(6,684)(6,683)Accumulated other comprehensive income

-2Total Shareholders' Equity14,75014,319Tota
'/>"/>

SOURCE MGC Diagnostics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. QBC Diagnostics Awarded GSA Contract
2. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
3. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
4. Ariosa Diagnostics to Present and Exhibit at the 16th International Conference on Prenatal Diagnosis and Therapy
5. ZINO Society Targets Medical Devices, Healthcare IT and Diagnostics
6. Quest Diagnostics To Speak At The Wells Fargo Securities 2012 Healthcare Conference
7. Breakthrough Prostate Cancer Diagnostics
8. NicOx Signs Worldwide Licensing Agreement With Rapid Pathogen Screening, Inc. For Ophthalmic Diagnostics
9. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
10. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
11. Quest Diagnostics to Release Second Quarter 2012 Financial Results on July 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... of, collaboration with investigators worldwide to develop new treatments for ... diverse forms of cancer ... on relapse rate of patients with early-stage breast cancer, - Four oral ... results of RECORD-1 study in renal cell ...
... Mich. and TOULOUSE, France, May 15 ... company,developing HDL-related compounds for the treatment of ... has completed a Phase I,clinical trial for ... candidates.,CER-002 is a peroxisome proliferator-activated receptor (PPAR),delta-specific ...
Cached Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2
(Date:4/24/2014)... spectrum disorders (ASD), resides in genes that are part ... the Icahn School of Medicine at Mount Sinai, who ... the United States and throughout the world. The ... in Autism Spectrum Disorders," was first published online in ... April 24. , ASD affects about one percent ...
(Date:4/24/2014)... at UT Southwestern Medical Center previously discovered that the ... adult heart lacks this ability. New research by the ... its incredible regenerative capability in adulthood, and the answer ... It is well-known that a major function of the ... But at the same time, oxygen is a highly ...
(Date:4/24/2014)... during and after colorectal surgery cut hospital stays by ... who led a study of the approach at Duke ... easier on patients before surgery, doing away with the ... After surgery, patients are encouraged to eat and move ... , Among findings published in the May 2014 issue ...
(Date:4/24/2014)... and the relevance of palliation in advanced cancer ... controlled trials (RCTs). This is the result of ... and Efficiency in Health Care (IQWiG), which has ... with external experts, IQWiG analysed studies on four ... melanoma, and pancreatic cancer. For this purpose, the ...
(Date:4/24/2014)... first in the world to discover a gene mutation ... , Ameloblastoma is an odontogenic tumour with a high ... found in the posterior of the lower jaw. Ameoloblastomas ... in the jaws as well as loss of several ... for surgery and the recurrence of ameloblastoma, but finding ...
Breaking Medicine News(10 mins):Health News:Genetic alterations in shared biological pathways as major risk factor for ASD 2Health News:Oxygen diminishes the heart's ability to regenerate, researchers discover 2Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3
... , ANNAPOLIS, Md., July 27 ... biodefense company developing medical countermeasures against biological and chemical threats, ... issuance of 2-year, 10% unsecured senior convertible notes ("Notes") and ... approximately $19.3 million. , , In connection ...
... , , ... How can hospitals build sustainable physician alignment? While hospitals ... few physician-relationship management programs demonstrate value. A new "thought ... Ensuring the Stability and Vitality of Today,s Hospitals," illustrates ...
... , FRANKLIN, Mass., July 27 ... focused on innovative cardiac and vascular medical device-based technologies, today ... fluid balancing capabilities provided by RenalGuard(R) from the Canadian Intellectual ... company,s first patent for RenalGuard in Canada. , , ...
... reveals more about how information is processed, stored in the ... read her name, your Oprah neuron will probably rev up. ... neurons in the brain,s hippocampus activate when people recognize a ... distorted or presented in less than perfect fashion. , "Different ...
... MINNEAPOLIS, July 27 Premier Visiting Nurse, part ... entered into a business relationship with Cardiocom (R) ... chronic illness. Cardiocom, the Experts in Telehealth(SM), is ... of award-winning telehealth solutions. , , ...
... , , BOSTON, July 27 ... and information management solutions, today announced a new contract with Booth ... use the AMICAS ONE Suite(TM) as its end-to-end radiology software solution, ... care. , , (Logo: ...
Cached Medicine News:Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 2Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 3Health News:PharmAthene, Inc. Announces $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 4Health News:Proper Physician-Relationship Management Ensures Hospital Stability and Vitality 2Health News:Canada Grants PLC Systems First Patent for RenalGuard(R) 2Health News:Famous Names Get Single Neurons Fired Up 2Health News:Premier Visiting Nurse Selects Cardiocom Telehealth Technology 2Health News:Booth Radiology Extends and Elevates Partnership With AMICAS 2Health News:Booth Radiology Extends and Elevates Partnership With AMICAS 3
Fine angled tips ideal for grasping delicate capsule. Angled 12 mm shafts with iris stop allows ease of movement in the anterior chamber. Flat handle with dull finish. Manufactured in titanium....
Gently curved shaft with 2 mm platform ideal for performing capsulorhexis through a tunnel incision. Flat handle with dull finish....
Fine angled 12 mm shafts and iris stop. Round handle for fingertip rotational control. Dull finish....
Gently curved jaws with fine angled sharp tips for puncture and grasping the capsule. Round handle is excellent for precise finger tip control. Made in titanium....
Medicine Products: